About Chemomab

Company Overview

Chemomab Ltd. is a clinical-stage biopharmaceutical company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

Chemomab is making great strides with its novel anti-CCL24 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders.

CM-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action.

Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver, skin and lung fibrosis.


  • Adi Mor, PhD

    Chief Executive Officer and Chief Scientific Officer

    Dr. Mor co-founded Chemomab in 2011. She has extensive knowledge and experience in immunology focusing on autoimmune and inflammatory diseases and broad experience in designing, promoting and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor earned her PhD in immunology from Tel Aviv University in the Department of Neurobiochemistry and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders.

  • Sigal Fattal, CPA, MBA

    Chief Financial Officer

    Ms. Fattal joined Chemomab in 2020. Ms. Fattal has a track record of over 20 years of extensive experience in leading IPOs, private investment, and M&A transactions, as well as establishing and managing effective financial, operational, and business activities in a vast range of industries. Ms. Fattal professional experience includes CFO positions at biotechnology companies, such as BiomX (NYSE: PHGE) and Evogene (NASDAQ: EVGN) (TASE: EVGN.TA). Ms. Fattal holds a BA in Accounting and Economics, with honors, and an MBA, both from Tel Aviv University.

  • Arnon Aharon, MD

    Chief Medical Officer

    Dr. Aharon joined Chemomab in 2016 as Head of Clinical Development. Prior to Chemomab, Dr. Aharon served as Chief Medical Officer at BioLineRx Ltd. (NASDAQ/TASE: BLRX), where he directed the development pipeline for oncology and immunology. Dr. Aharon’s professional experience includes multiple senior management positions at biotechnology companies, such as Pharmos Ltd. (NASDAQ/TASE: PARX), Thrombotech Ltd., and LycoRed Ltd. Dr. Aharon is a member of several industry advisory groups and provides consulting services to biotechnology companies and academic institutions. Dr. Aharon earned his MD from the University of Tel Aviv, Israel, and has experience in internal medicine.

  • Sharon Elkobi, MSc, MBA

    VP of Business Development

    Mr. Elkobi joined Chemomab in 2019 with over 12 years of experience. Prior to joining Chemomab, Mr. Elkobi served as VP of Business Development at Neurim Pharmaceuticals Ltd. and as part of the senior leadership team, led the commercialization of Slenyto, the world’s first approved sleep drug for children with autism spectrum disorder and successfully signed multiple strategic global license and co-development deals. Prior to Neurim, Mr. Elkobi held a series of business development, sales and marketing positions at Medison Pharma Ltd., and at Teva Pharmaceuticals. Mr. Elkobi earned both his MSc in biochemistry and biotechnology and MBA from Tel Aviv University.

  • Michal Segal-Salto, PhD

    VP of Research and Development

    Joining Chemomab in 2015, Dr. Segal-Salto has over 15 years of experience in cell biology, molecular biology and biochemistry. She was awarded her PhD from the Weizmann Institute of Science in Rehovot, Israel. Dr. Segal-Salto has been successfully leading the R&D team since early preclinical stages through clinical translation.

  • Sharon Hashmueli, PhD

    CMC and Regulatory Affairs

    Dr. Hashmueli joined Chemomab in 2016 as Head of Chemistry, Manufacturing and Controls and Regulatory Affairs, with over 15 years of experience in drug development. Prior to joining Chemomab, Dr. Hashmueli worked at cCAM Biotherapeutics (acquired by Merck in 2015), developing a novel immune checkpoint inhibitor for cancer, and at Protalix Biotherapeutics, where she played a significant role in the development of Elelyso, an FDA approved treatment (marketed by Pfizer) for Gaucher disease. Dr. Hashmueli holds a PhD in biotechnology and food engineering from the Technion – Israel Institute of Technology.

Boards of Directors

  • Stephen Squinto

    Chairman of the Board

    Stephen Squinto is an Executive Partner with OrbiMed. He was a co-founder of Alexion Pharmaceuticals, Inc. and recently served as its Executive Vice President and Chief Global Operations Officer. Prior to 2013, he was Alexion's Global Head of Research and Development. From 1988 to 1992, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc. Prior to Regeneron, he held a joint academic position at both the Tulane University and Louisiana State University Medical Schools. Dr. Squinto obtained his PhD in biochemistry and biophysics from Loyola University in Chicago. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work.

  • Adi Mor

    Chief Executive Officer & Co-Founder

    Adi Mor co-founded Chemomab in 2011 and is serving as the company’s CEO since. She has extensive knowledge and experience in immunology focusing on autoimmune and inflammatory diseases and broad experience in designing, promoting and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor earned her PhD in immunology from Tel Aviv University in the Department of Neurobiochemistry and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders.

  • Alan Moses

    Board Member

    Alan Moses, spent 14 years at Novo Nordisk, held multiple roles and rising to the position of Senior Vice President and Global Chief Medical Officer. Dr. Moses was co-founder and co-director of the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT and served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center in Boston and was appointed Professor of Medicine at Harvard Medical School. Dr. Moses earned his M.D. from the Washington University School of Medicine in St. Louis, worked at the National Institutes of Health and completed subspecialty clinical training in Endocrinology at Tufts New England Medical Center.

  • Claude Nicaise

    Board Member

    Claude Nicaise is the owner of Clinical Regulatory Services, a company providing advice on clinical and regulatory matters to biotechnology companies. Dr. Nicaise was a Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Pharmaceuticals from 2008 to 2014. From 1983 to 2008, Dr. Nicaise served in various positions of increasing responsibility at Bristol-Myers Squibb, including senior positions such as Vice President of Global Development, Vice-President of Worldwide Regulatory Science and Strategy, and leadership positions in Oncology, Infectious Disease, and Neuroscience development. Dr. Nicaise is a board member in several public and private companies and received his medical degree from the Université Libre de Bruxelles in Belgium

  • Joel Maryles

    Board Member

    Joel Maryles has held numerous senior positions in the financial sector over the past three decades. Mr. Maryles was a Partner at OurCrowd from 2015 to 2018. From 2007 to 2012, Mr. Maryles was a portfolio manager of T-Cubed Investments LP, an equity hedge fund that he founded. From 1996 to 2006, he was a Managing Director at Citigroup Investment Banking where, in addition to his role as a senior technology banker, he founded and managed the Israeli investment banking operations for Citigroup/Salomon Smith Barney. Previously, Mr. Maryles held various senior positions at Furman Selz, a U.S.-based investment bank, including Managing Director focused on Israeli technology and healthcare transactions and was an Investment Officer at First Chicago Investment Advisors. Mr. Maryles holds a B.Sc. degree in engineering from the University of Illinois and an M.B.A. from the University of Chicago.

  • Neil Cohen

    Board Member

    Neil Cohen served as interim CEO of Anchiano Therapeutics (NASDAQ: ANCN) from October 2020 until its merger with Chemomab in March 2021. He has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994, he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until 2019. Mr. Cohen has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired or completed successful initial public offerings. He is a venture partner at SKY, an Israeli middle-market private equity firm, at Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at the Rothschild Bioscience Unit of N M Rothschild & Sons Limited in London. Mr. Cohen received a B.A. and M.A., with first class honors, from Oxford University.

  • Nissim Darvish

    Board Member

    Nissim Darvish is a Venture Partner at OrbiMed Israel. Dr. Darvish is a veteran of the life science industry, with over 20 years of experience covering biotech, medical technology development, corporate leadership and investment management. Dr. Darvish spent 8 years with Pitango, where he was a General Partner managing life sciences investments. Previously, Dr. Darvish was the founder and CEO of Impulse Dynamics, which he led for 6 years, culminating in a $250 million realization event. Dr. Darvish obtained his MD and PhD in biophysics and physiology from the Technion in Israel and subsequently conducted his postdoctoral research at the NIH. He has published over 100 patents, authored over 20 publications and received 8 distinguished prizes and awards.

Scientific Advisory Board

Primary Sclerosing Cholangitis and Non-Alcoholic SteatoHepatitis

  • Scott L. Friedman, MD

    Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA

    Prof. Friedman is Chief of Liver Diseases and Dean of Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai. His pioneering hepatic fibrosis research has been supported by the NIH since 1986 and his mentorship of over 80 trainees have helped fibrosis emerge as a new hepatology therapeutic specialty with exciting potential. Prof.. Friedman was a Senior Fulbright Scholar at the Weizmann Institute, Israel, in 1995 and President of the American Association for the Study of Liver Diseases (AASLD) in 2009. He received the International Hans Popper Prize, the EASL International Recognition Award, the AASLD Distinguished Achievement Award and the American Liver Foundation Distinguished Award. Prof. Friedman is a Fellow of the AASLD, AGA, ACP and AAAS.

  • Massimo Pinzani, MD, PhD, FRCP, FAASLD

    University College London, London, UK

    Prof. Massimo Pinzani is Professor of Medicine at University College London (UCL), London, United Kingdom. He is a clinical and translational hepatologist, Sheila Sherlock Chair of Hepatology and Director of the UCL Institute for Liver and Digestive Health, Division of Medicine. He is one of the pioneers in the research dedicated to cellular and molecular mechanisms of liver fibrosis and relative diagnostic and therapeutic approaches. His current research is centered on regenerative medicine, in particularon the development of extracellular matrix scaffolds of the liver, pancreas and small intestine for cell bioengineering and 3D disease modelling. Professor Pinzani’s research has been presented in more than 200 original peer-reviewed publications. He has served in the governing and scientific boards of major international organizations in hepatology and gastroenterology, and as Editor in Chief and Associate Editor of top peer reviewed international journals in gastroenterology and hepatology. He is Educational Councilor and member of the governing board of the European Association for the Study of the Liver (EASL). He is currently Chairman and Co-founder of Engitix Ltd., a UCL spin-off company dedicated to tissue engineering and regenerative medicine with particular focus on the liver and digestive tract.

  • Arun Sanyal, MD

    The Virginia Commonwealth University, Richmond, VA, USA

    Prof. Arun Sanyal, is a Professor of Medicine, Physiology and Molecular Pathology in the Division of Gastroenterology, Hepatology and Nutrition at the Virginia Commonwealth University (VCU) School of Medicine. Dr. Sanyal is Special Council Board Member of NIAAA (National Institute on Alcohol Abuse and Alcoholism) and has been a past President of the AASLD (American Association for the Study of Liver Diseases). He has chaired committees at the NIDDK NASH Clinical Research Network and the NIH Hepatobiliary Study Section. Prof. Sanyal was instrumental in establishing the international Liver Forum for NASH, and he continues to serve as a Chair of this organization, comprising industry, academia and regulatory bodies from the USA and EU. Prof. Sanyal also leads several major drug trials for the treatment of NASH. He has published over 300 papers in leading medical journals and periodicals throughout his career.

  • Eric Gershwin, MD, MACP, MACR

    The University of California, Davis, CA, USA

    Prof. M. Eric Gershwin is a Distinguished Professor of Medicine as well as the Jack and Donald Chia Professor of Medicine. He is also Chief of the Division of Allergy and Clinical Immunology at the University of California School of Medicine in Davis. He graduated from Stanford Medical School and trained in internal medicine and then immunology at Tufts University-New England Medical Center and the National Institutes of Health. Prof. Gershwin subsequently joined the UC Davis faculty and has been Division Chief since 1982. The NIH has continuously funded his work since 1975. Prof. Gershwin has published more than 20 books, 800 experimental papers, and 200 book chapters or review articles. He is triple-boarded in rheumatology, allergy-immunology and internal medicine. He is Editor in Chief of both the Journal of Autoimmunity and Clinical Reviews in Allergy and Immunology and serves on the editorial board of multiple other journals. Gershwin is listed in the top 1% of all cited authors in PubMed in immunology and has chaired committees for the NIH, NSF, USDA, FTC and FDA. He is an authority on autoimmune liver disease and was the first person to clone an autoantigen, the immunodominant mitochondrial autoantigen of primary biliary cholangitis.

Systemic Sclerosis

  • Marco Matucci-Cerinic, MD, PhD, FRCP, FBSRhon

    University of Florence, Florence, Italy

    Prof. Marco Matucci-Cerinic is Professor of Rheumatology and Medicine at the Department of Musculoskeletal Medicine and Director of the Rheumatology Department (AVC) and of the Division of Rheumatology at the Azienda Ospedaliera Universitaria Careggi (AOUC) in Florence, Italy. In addition, Prof. Matucci-Cerinic is Professor of Rheumatology at the University of Florence, Italy. He has published more than 600 peer-reviewed manuscripts broadly covering the field of rheumatology, particularly on the pathogenesis, clinical features and treatment of scleroderma, spondyloarthritis and osteoarthritis. He has also served on various international and national committees. Prof. Matucci-Cerinic has served as the EULAR General Secretary and as Chairman of the EULAR Scleroderma Trial and Research Group (EUSTAR). He is currently Chairman of the World Scleroderma Foundation and Editor in Chief of the Journal of Scleroderma & Related Diseases. He is also Associate Editor of Arthritis Research & Therapy and Clinical & Experimental Rheumatology, past Associate Editor and Co-Editor of Rheumatology. He serves on the boards of Annals of the Rheumatic Diseases, Rheumatology, Journal of Rheumatology, Scandinavian Journal of Rheumatology and other rheumatology journals.

  • Yanick Allanore, MD

    Paris Descartes University, Paris, France

    Prof. Allanore is Professor of Rheumatology in Paris Descartes University with a broad background in autoimmune diseases and systemic sclerosis (SSc) in particular. Prof. Allanore’s research includes clinical aspects of SSc with particular interest in the cardiovascular complications and biomarkers. In addition, Prof. Allanore is the head of a research team at Cochin Institute working on immunogenetics in SSc. He is involved in several international organizations and networks and was elected Chairman of the European Network Working on SSc (EUSTAR) in 2016.

  • Oliver Distler, MD

    University Hospital Zurich, Zurich, Switzerland

    Prof. Oliver Distler is Professor of Rheumatology and Director of the Department of Rheumatology at the University of Zurich, Switzerland. His main research interests in systemic sclerosis are the molecular mechanisms leading to microvascular lesions, the biological action of pro-fibrotic mediators, validation of biomarkers and design of proof-of-concept trials as well as phase 3 trials. Professor Distler is an editorial board member of several rheumatology journals and Treasurer of EUSTAR.

  • Dinesh Khanna, MD

    University of Michigan, Ann Arbor, MI, USA

    Prof. Khanna is a Professor of Medicine and Director of the University of Michigan (UM) Scleroderma Program. UM Scleroderma Program offers a tertiary referral center for patients with scleroderma and related conditions. The program sees approximately 1,200-1,500 unique patient visits on an annual basis and has 3 full-time faculty members and 5 coordinators. Prof. Khanna has expertise in developing and validating outcome measures for clinical trials and led the development of the Combined Response Index in Systemic Sclerosis (an NIH/NIAMS-funded effort), which is now included as primary, secondary and exploratory measures in ongoing trials. Dr. Khanna’s research has focused on the development of outcome measures and refinement of trial design in scleroderma. Based on his expertise in trial design and outcome measures, he co-led the EULAR Points to Consider recommendations for trial design in SSc and will chair a project with the NIH and his FDA colleagues to develop a white paper for clinical trials in SSc.

  • Francesco Del Galdo, MD, PhD

    University of Leeds, Leeds, UK

    Prof. Francesco Del Galdo is an Associate Professor in the Head of Scleroderma Program at the Leeds Institute of Rheumatic and Musculoskeletal Medicine. In the Scleroderma Center of Thomas Jefferson University in Philadelphia, PA, USA, he pioneered the application of Optical Coherence Tomography, MRI and serum biomarkers of overall fibrosis as outcome measures of activity and early diagnosis in Scleroderma. He has over a decade of experience in managing rheumatological conditions including systemic sclerosis, and he runs a prestigious research program within the Leeds Institute on personalized medicine for patients at risk of rheumatic diseases. As an internationally renowned leader in systemic sclerosis, Prof. Del Galdo is the author of more than 100 scientific journal publications and books.

Scientific Founder

  • Jacob George, MD

    Director of the Heart Center, Kaplan Medical Center; Affiliated to the Hebrew University, Israel

    Prof. Jacob George founded Chemomab in 2011 based on more than 20 years of prior research in inflammation, cardiovascular medicine and autoimmune diseases. He serves as a full Professor of Cardiology in the School of Medicine at the Hebrew University of Jerusalem and is the current director of the Heart Center at Kaplan Medical Center in Rehovot, Israel. Prof. George has published more than 400 papers and has written and edited several books. Prof. George serves on the editorial board of fifteen scientific journals and his research mainly centers on the role of the immune system in various inflammatory disorders. Prof. George serves as an advisor to numerous pharmaceuticals companies and has been engaged in promoting a series of pharmaceutical products from discovery into clinical trials. He is the co-founder and previous CSO of VBL therapeutics and a founder of Cognyxx pharmaceuticals.